A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: XEN-101; Drug: Placebo

• Registration Number: NCT05667129
• Lead Sponsor: Xeno Biosciences

Brief Summary

The goal of this study is to assess the safety and tolerability of single and multiple ascending doses of XEN-101

Detailed Description

Single ascending dose (SAD) study to evaluate the safety and tolerability of XEN-101 in healthy participants. Multiple ascending dose (MAD) study to evaluate the safety and tolerability of XEN-101 in healthy participants.

Study Timeline

• Study Start: 2022-12-01
• Study First Submitted: 2022-12-19
• Study First Submitted QC: 2022-12-27
• Study First Posted: 2022-12-28
• Primary Completion: 2023-05-30
• Study Completion: 2023-05-30
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-19
• Last Update Posted: 2023-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 97

Inclusion Criteria

1. Male or female, age 18-60 years at Screening
2. SAD part: BMI 18-30 kg/m2; MAD part 2a: BMI 22-27 kg/m2; MAD Part 2b: BMI 30-40 kg/m2
3. Stable body weight for at least 3 months (fluctuation of less than or equal to 5% and not exceeding 4 kg) in all study Parts.
4. Women of childbearing potential shall agree to use an adequate method of contraception from the date of signing of the informed consent, throughout the study, and for 4 weeks after the final (EOS) study visit. In addition, they must be advised not to donate ova during this period. From the date of signing of the informed consent, throughout the study, and for 8 weeks after the last dose of study medication, non sterilized male subjects who are sexually active with a female partner of childbearing potential must use barrier contraception (e.g., condom with spermicidal cream or jelly). In addition, they must be advised not to donate sperm during this period.
5. Females of childbearing potential must have a negative pregnancy test at Screening and on Day -1 (baseline)
6. Able to provide Informed Consent
7. Willing and able to comply with this protocol and procedures, including feces pro-cessing and be available for the entire duration of the study.

Exclusion Criteria

1. Currently enrolled in another investigational device or drug study, or less than 30 days or 5 time the half-life of the drug candidate, whichever is longer, passed at Screening since ending the treatment period the previous investigational device or drug study
2. History of diabetes mellitus, hypertension, sleep apnea, liver, kidney, auto-immune disease
3. Current nicotine use or in past 6 months (smoking, vaping, etc)
4. Uncontrolled psychiatric disorder
5. History of eating disorder (e.g. anorexia nervosa, bulimia, binge-eating disorder)
6. History of alcohol, nicotine, or substance misuse in the last 5 years
7. Use of antibiotics, antivirals, antifungals during past 3 months
8. Use of proton pump inhibitors or non-stable dose antidepressants
9. Use of anti-obesity medications (e.g. GLP-analogues, stimulants, bupropri-on/naltrexone, etc.)
10. Use of obesogenic medications (e.g. anti-diabetics, anti-convulsives, anti-histamines, beta-blockers, etc.) in past 3 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
XEN-101	XEN-101	Capsule formulation
Placebo	Placebo	Capsule formulation

Primary Outcome Measures

Name	Time	Method
The frequency of adverse events (Safety of XEN-101)	From Day 1 through end of study (Day 7 SAD; Day 38 MAD)	assessing the type and frequency of adverse events

Trial Locations

Locations (1)

CRU Hungary - Early Phase Unit; 🇭🇺 Kistarcsa, Hungary